Premium
P1‐181: State‐Dependent Alterations in CSF Aβ42 Levels in Cognitively‐Intact Elderly With Late Life Major Depression
Author(s) -
Pomara Nunzio,
Bruno Davide,
Reichert Chelsea,
Sarreal Antero,
Hernando Raymundo,
Zetterberg Henrik,
Blennow Kaj
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.929
Subject(s) - depression (economics) , late life depression , medicine , cerebrospinal fluid , longitudinal study , neuropsychology , psychology , depressive symptoms , cognition , psychiatry , pathology , economics , macroeconomics
Depression has been linked to Alzheimer’s disease (AD) as either an increased risk factor for its development or as a prodromal symptom. The neurobiological basis for such association, however, remains poorly understood. Numerous studies have examined whether changes in amyloid beta (Aβ) metabolism, which are implicated in AD pathogenesis, are also found in depression. In this paper, we investigated the relationship between depressive symptoms and cerebrospinal fluid (CSF) Aβ indices, in healthy cognitively normal elderly with late-life major depression (LLMD) and controls, by using a longitudinal approach, which is a novel contribution to the literature. Significantly lower levels of CSF Aβ42 were observed in the LLMD group at baseline and were associated with more severe depressive symptoms. During longitudinal follow up, the depressed group remained cognitively unchanged, but was significantly less depressed than at baseline. A greater improvement in depressive symptoms was associated with increases in CSF Aβ42 levels in both groups. Increases in CSF Aβ42 and Aβ40 were also associated with increased CSF total tau levels. Our results suggest that LLMD may be associated with state-dependent effects of CSF Aβ42 levels. Future studies should determine if the association reflects state-dependent changes in neuronal activity and/or brain amyloid burden in depression.